Showing results (511-520 of 519) with videos related to

Sort By:
Pageof 52
You have reached the last page of results.This site can display upto 519 results.
Journal of Viral Hepatitis|August 2, 2014
The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1T Oze, N Hiramatsu, T Yakushijin, et al.
Human Genetics|August 14, 2001
Distribution of glucose-6-phosphate dehydrogenase mutations in Southeast AsiaK Iwai, A Hirono, H Matsuoka, et al.
Journal of Cardiovascular Pharmacology|October 23, 1997
Physiological role of Ca2+-permeable nonselective cation channel in endothelin-1-induced contraction of rabbit aortaT Komuro, S Miwa, X F Zhang, et al.
Cancer Gene Therapy|June 20, 2015
Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgeryS Yano, Y Hiroshima, A Maawy, et al.
Journal of Viral Hepatitis|April 11, 2014
Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirinN Harada, N Hiramatsu, T Oze, et al.
American Journal of Hematology|April 1, 1983
The occurrence of different levels of G gamma chain and of the A gamma T variant of fetal hemoglobin in newborn babies from several countriesT H Huisman, A L Reese, M B Gardiner, et al.
Journal of Viral Hepatitis|June 26, 2009
Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirinT Oze, N Hiramatsu, T Yakushijin, et al.
Journal of Viral Hepatitis|June 26, 2009
Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirinN Hiramatsu, T Oze, T Yakushijin, et al.
Clinical Nephrology|September 2, 1998
Dihydropyridine type calcium channel blocker-induced turbid dialysate in patients undergoing peritoneal dialysisK Yoshimoto, S Saima, Y Nakamura, et al.
Pageof 52